Cargando…
The Novel Serine/Threonine Protein Kinase LmjF.22.0810 from Leishmania major May Be Involved in the Resistance to Drugs such as Paromomycin
The identification and clarification of the mechanisms of action of drugs used against leishmaniasis may improve their administration regimens and prevent the development of resistant strains. Herein, for the first time, we describe the structure of the putatively essential Ser/Thr kinase LmjF.22.08...
Autores principales: | Vacas, Andrés, Fernández-Rubio, Celia, Algarabel, Miriam, Peña-Guerrero, José, Larrea, Esther, Rocha Formiga, Fabio, García-Sosa, Alfonso T., Nguewa, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920834/ https://www.ncbi.nlm.nih.gov/pubmed/31718000 http://dx.doi.org/10.3390/biom9110723 |
Ejemplares similares
-
LmjF.22.0810 from Leishmania major Modulates the Th2-Type Immune Response and Is Involved in Leishmaniasis Outcome
por: Vacas, Andrés, et al.
Publicado: (2020) -
Identification of the Leishmania major Proteins LmjF07.0430, LmjF07.0440, and LmjF27.2440 as Components of Fatty Acid Synthase II
por: Gurvitz, Aner
Publicado: (2009) -
The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells
por: Larrea, Esther, et al.
Publicado: (2022) -
In Leishmania major, the Homolog of the Oncogene PES1 May Play a Critical Role in Parasite Infectivity
por: Algarabel, Miriam, et al.
Publicado: (2021) -
Discovery and Validation of Lmj_04_BRCT Domain, a Novel Therapeutic Target: Identification of Candidate Drugs for Leishmaniasis
por: Peña-Guerrero, José, et al.
Publicado: (2021)